Remus Pharmaceuticals Balance Sheet Annual
BSE: - | NSE: - | ISIN: - | Sector: -772.00 -1.75 (-0.23%)Updated : 16 Jun 2026
| Fiscal Period | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Period End Date | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
| Total Liabilities Shareholders' Equity | 578.65 | 432.64 | 257.27 | 34.66 |
| Cash Equivalents | 12.88 | 0.00 | 26.87 | 3.04 |
| Other Liabilities Total | 0.62 | 0.67 | 0.46 | 0.28 |
| Long Term Debt | 5.67 | 3.33 | 1.56 | 7.09 |
| Common Stock Total | 11.78 | 5.89 | 1.47 | 1.09 |
| Other Current Assets Total | 18.18 | 2.71 | - | - |
| Total Assets | 578.65 | 432.64 | 257.27 | 34.66 |
| Current Portof LT Debt/ Capital Leases | 1.01 | 0.51 | 0.21 | 0.85 |
| Total Equity | 350.99 | 255.86 | 86.86 | 19.14 |
| Long Term Investments | 257.21 | 195.33 | 20.55 | 20.62 |
| Retained Earnings( Accumulated Deficit) | 339.21 | 57.19 | 34.83 | 13.89 |
| Total Common Shares Outstanding | 1.18 | 1.18 | 1.18 | 0.87 |
| Property/ Plant/ Equipment Total- Gross | 8.28 | 10.28 | 4.09 | 3.46 |
| Tangible Book Valueper Share Common Eq | 290.24 | 209.50 | 65.76 | 21.99 |
| Goodwill Net | 8.73 | 8.73 | 9.34 | - |
| Total Liabilities | 227.66 | 176.78 | 170.42 | 15.53 |
| Total Debt | 27.07 | 22.98 | 11.55 | 7.94 |
| Short Term Investments | 42.03 | 20.04 | 2.48 | - |
| Cashand Short Term Investments | 54.91 | 24.56 | 29.35 | 3.04 |
| Total Receivables Net | 149.49 | 141.18 | 137.51 | 8.02 |
| Notes Payable/ Short Term Debt | 17.37 | 17.48 | 8.34 | 0.00 |
| Deferred Income Tax | 32.51 | 22.90 | 0.00 | 0.00 |
| Accounts Receivable- Trade Net | 139.84 | 108.03 | 114.48 | 4.85 |
| Property/ Plant/ Equipment Total- Net | 17.80 | 6.83 | 2.28 | 2.51 |
| Minority Interest | 36.74 | 26.69 | 17.48 | - |
| Total Current Liabilities | 149.10 | 121.53 | 149.48 | 8.16 |
| Total Inventory | 72.06 | 52.60 | 42.88 | 0.29 |
| Accounts Payable | 76.04 | 71.29 | 93.70 | 3.53 |
| Other Currentliabilities Total | 54.68 | 32.16 | 47.16 | 3.75 |
| Total Long Term Debt | 8.69 | 4.99 | 3.00 | 7.09 |
| Intangibles Net | 0.24 | 0.26 | 0.03 | 0.05 |
| Other Long Term Assets Total | 0.03 | 0.11 | 1.47 | 0.14 |
| period Length | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 294.64 | 221.37 | 209.74 | 11.34 |
| Capital Lease Obligations | 3.02 | 1.66 | 1.44 | - |
| Accumulated Depreciation Total | - | -3.45 | -1.82 | -0.94 |
| Accrued Expenses | - | 0.09 | 0.07 | 0.02 |
| Other Equity Total | - | 142.35 | 0.08 | - |
| Prepaid Expenses | - | 0.32 | - | - |
| Additional Paid- In Capital | - | 50.43 | 50.47 | 4.17 |
| Cash | - | 4.52 | - | - |
| Note Receivable- Long Term | - | 0.01 | 13.88 | 0.00 |
*All figures in crores except per share values
Remus Pharmaceuticals Quick Links
Remus Pharmaceuticals Dividend Remus Pharmaceuticals Bonus Remus Pharmaceuticals News Remus Pharmaceuticals AGM Remus Pharmaceuticals Rights Remus Pharmaceuticals Splits Remus Pharmaceuticals Board Meetings Remus Pharmaceuticals Key Metrics Remus Pharmaceuticals Shareholdings Remus Pharmaceuticals Profit Loss Remus Pharmaceuticals Cashflow Remus Pharmaceuticals Q1 Results Remus Pharmaceuticals Q2 Results Remus Pharmaceuticals Q3 Results Remus Pharmaceuticals Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
2,903.45+148.70(5.40%)
1,749.00+59.75(3.54%)
251.40+7.60(3.12%)
348.70-5.25 (-1.48%)
1,327.00-13.35 (-1.00%)
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.